On May 25, 2023, FDA approved Paxlovid for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. FDA has determined that Paxlovid is safe and effective when used in accordance with the FDA-approved labeling.